[go: up one dir, main page]

ES2172069T3 - Derivado tetrapeptidico. - Google Patents

Derivado tetrapeptidico.

Info

Publication number
ES2172069T3
ES2172069T3 ES98115259T ES98115259T ES2172069T3 ES 2172069 T3 ES2172069 T3 ES 2172069T3 ES 98115259 T ES98115259 T ES 98115259T ES 98115259 T ES98115259 T ES 98115259T ES 2172069 T3 ES2172069 T3 ES 2172069T3
Authority
ES
Spain
Prior art keywords
tetrapeptidic
derivative
dolastatin
salt
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98115259T
Other languages
English (en)
Inventor
Kyoichi Sakakibara
Masaaki Gondo
Koichi Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Teikoku Hormone Manufacturing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26525532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teikoku Hormone Manufacturing Co Ltd filed Critical Teikoku Hormone Manufacturing Co Ltd
Application granted granted Critical
Publication of ES2172069T3 publication Critical patent/ES2172069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN DERIVADO DE TETRAPEPTIDO REPRESENTADO POR LA FORMULA SIGUIENTE, O A UNA SAL DEL MISMO, EL CUAL TIENE UNA ACTIVIDAD CITOSTATICA MAYOR QUE LA DOLASTATINA 10, Y ES UTIL COMO AGENTE ANTITUMORAL: DONDE:
ES98115259T 1991-08-09 1992-08-06 Derivado tetrapeptidico. Expired - Lifetime ES2172069T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22353491 1991-08-09
JP22539191 1991-08-12

Publications (1)

Publication Number Publication Date
ES2172069T3 true ES2172069T3 (es) 2002-09-16

Family

ID=26525532

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98115259T Expired - Lifetime ES2172069T3 (es) 1991-08-09 1992-08-06 Derivado tetrapeptidico.
ES92916961T Expired - Lifetime ES2144421T3 (es) 1991-08-09 1992-08-06 Nuevo derivado tetrapeptidico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES92916961T Expired - Lifetime ES2144421T3 (es) 1991-08-09 1992-08-06 Nuevo derivado tetrapeptidico.

Country Status (13)

Country Link
US (2) US6004934A (es)
EP (2) EP0598129B1 (es)
JP (1) JP2618597B2 (es)
KR (2) KR0185440B1 (es)
AT (2) ATE215962T1 (es)
AU (2) AU662551B2 (es)
CA (1) CA2115355C (es)
DE (2) DE69230824T2 (es)
DK (2) DK0934950T3 (es)
ES (2) ES2172069T3 (es)
GR (1) GR3033397T3 (es)
SG (1) SG87056A1 (es)
WO (1) WO1993003054A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
EP0642530B1 (en) * 1992-05-20 1998-08-12 BASF Aktiengesellschaft Derivatives of dolastatin
RU2132334C1 (ru) * 1992-12-16 1999-06-27 Басф Акциенгезельшафт Аналог долостатина
ATE282630T1 (de) * 1993-10-01 2004-12-15 Teikoku Hormone Mfg Co Ltd Dolastatin-derivate
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1996033212A1 (fr) * 1995-04-21 1996-10-24 Teikoku Hormone Mfg. Co., Ltd. Nouveaux derives peptidiques
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
ATE293638T1 (de) * 1997-09-24 2005-05-15 Univ Arizona Synthetische antineoplastische wirkstoffe abgeleitet von dolastatin 15 sowie verfahren zu ihrer herstellung
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001041789A1 (fr) * 1999-12-07 2001-06-14 Santen Pharmaceutical Co., Ltd. Medicament contre les rhumatismes contenant un derive tetrapeptidique en tant qu'ingredient actif
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
KR20010079252A (ko) * 2001-06-27 2001-08-22 홍진의 주름형 드럼을 갖는 드럼 필터
AU2002362579B2 (en) * 2001-09-20 2007-09-06 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide derivative crystals
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
NZ547633A (en) * 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US8288352B2 (en) * 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP1917020B1 (en) 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
PL2474557T3 (pl) 2007-07-16 2015-02-27 Genentech Inc Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
KR101559595B1 (ko) 2007-07-16 2015-10-12 제넨테크, 인크. 인간화 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
IL295449A (en) 2008-01-31 2022-10-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
US9278996B2 (en) 2012-09-20 2016-03-08 Celltrion, Inc. Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
JP6636925B2 (ja) 2013-12-17 2020-01-29 ノバルティス アーゲー 細胞障害性ペプチドおよびその抱合体
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
JP2017519740A (ja) * 2014-05-28 2017-07-20 アジェンシス，インコーポレイテッド ドラプロイン‐ドライソロイインペプチド誘導体
MX2016016515A (es) 2014-06-13 2017-04-27 Novartis Ag Derivados de auristatina y conjugados de los mismos.
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP6928354B2 (ja) 2015-07-24 2021-09-01 ペティット，ジョージ，ロバート クインスタチン化合物
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
BR112018016008A2 (pt) * 2016-03-29 2018-12-18 Toray Industries, Inc. derivado de peptídeo ou o sal farmaceuticamente aceitável do mesmo, conjugado ou um sal farmaceuticamente aceitável do mesmo, e, agente citotóxico.
EP3888691A1 (en) 2016-11-14 2021-10-06 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2021084532A1 (en) * 2019-10-28 2021-05-06 Ariel Scientific Innovations Ltd. Dolastatin 10 analog
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides

Also Published As

Publication number Publication date
DE69230824D1 (de) 2000-04-27
US6004934A (en) 1999-12-21
US5654399A (en) 1997-08-05
DE69230824T2 (de) 2000-07-27
DE69232552D1 (de) 2002-05-16
JP2618597B2 (ja) 1997-06-11
DK0934950T3 (da) 2002-07-29
SG87056A1 (en) 2002-03-19
EP0598129A4 (en) 1995-10-25
DK0598129T3 (da) 2000-07-03
DE69232552T2 (de) 2002-10-31
ATE215962T1 (de) 2002-04-15
EP0598129B1 (en) 2000-03-22
AU2415292A (en) 1993-03-02
WO1993003054A1 (en) 1993-02-18
CA2115355C (en) 2007-09-11
ES2144421T3 (es) 2000-06-16
GR3033397T3 (en) 2000-09-29
EP0934950A1 (en) 1999-08-11
AU662551B2 (en) 1995-09-07
ATE190983T1 (de) 2000-04-15
KR100202474B1 (en) 1999-06-15
EP0598129A1 (en) 1994-05-25
EP0934950B1 (en) 2002-04-10
AU673487B2 (en) 1996-11-07
KR0185440B1 (ko) 1999-04-01
CA2115355A1 (en) 1993-02-18
AU2001095A (en) 1995-07-20

Similar Documents

Publication Publication Date Title
ES2172069T3 (es) Derivado tetrapeptidico.
ES2183473T3 (es) Derivados de acido piridonacarboxilico como agentes antibacterianos.
ES2179071T3 (es) Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada.
ES2156150T3 (es) Combinacion terapeutica que contiene interferon.
ES2137456T3 (es) Agente de tratamiento de las enfermedades hepato-biliares.
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
ES2136725T3 (es) Utilizacion de 2-amino-6-n-propil-amino-4,5,6,7-tetrahidrobenzotiazol (pramipexol) como medicamento con efecto antidepresivo.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
CO4770892A1 (es) Composiciones desinfectantes y proceso para desinfectar su- perficies
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
KR940008689A (ko) 항네프로제증후군제
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
ATE190498T1 (de) Stabile, pharmazeutische zusammensetzungen die hybrid alpha-interferon enthalten
ES2097423T3 (es) Analogos de vitamina d3.
GT199900064A (es) Derivados de higromicina a.
BR9910305A (pt) Vacina
CO4750591A1 (es) Procedimiento de lucha contra los insectos
ES2153689T3 (es) Pastilla de jabon antiseptico.
HN2000000090A (es) Sal difosfato de un derivado de 4sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica.
ES2081463T3 (es) 1-alquil-3-(acilamino)-epsilon-caprolactamas como mejoradores del aprendimiento y memoria y composiciones farmaceuticas que las contienen.
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.
ES2052530T3 (es) Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina.
ES2083490T3 (es) 3,5-diyodo-l-tironina para la supresion de tsh y el tratamiento del bocio.
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 934950

Country of ref document: ES